Baker Ellis Asset Management LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,191 shares of the company’s stock after buying an additional 143 shares during the quarter. Johnson & Johnson accounts for about 1.2% of Baker Ellis Asset Management LLC’s holdings, making the stock its 18th biggest position. Baker Ellis Asset Management LLC’s holdings in Johnson & Johnson were worth $4,391,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Lenox Wealth Advisors Inc. lifted its position in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Johnson & Johnson by 241.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after purchasing an additional 841 shares in the last quarter. Ullmann Financial Group Inc. bought a new position in shares of Johnson & Johnson during the first quarter valued at about $186,000. Taylor Wealth Management Partners lifted its position in shares of Johnson & Johnson by 19.8% during the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after purchasing an additional 250 shares in the last quarter. Finally, Puplava Financial Services Inc. bought a new position in shares of Johnson & Johnson during the second quarter valued at about $202,000. Hedge funds and other institutional investors own 65.93% of the company’s stock.

Johnson & Johnson (JNJ) opened at $139.49 on Wednesday. The company has a market cap of $375,468.03, a P/E ratio of 19.57, a P/E/G ratio of 2.84 and a beta of 0.82. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $144.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. Johnson & Johnson’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.68 earnings per share. equities analysts forecast that Johnson & Johnson will post 7.28 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.41%. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

COPYRIGHT VIOLATION WARNING: “Baker Ellis Asset Management LLC Has $4.39 Million Stake in Johnson & Johnson (JNJ)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/11/15/baker-ellis-asset-management-llc-has-4-39-million-stake-in-johnson-johnson-jnj.html.

JNJ has been the topic of a number of recent analyst reports. UBS AG reissued a “buy” rating and set a $148.00 price target (up from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Credit Suisse Group began coverage on shares of Johnson & Johnson in a research report on Thursday, July 20th. They set an “outperform” rating and a $148.00 price target on the stock. BTIG Research lowered shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price objective on the stock. in a research report on Friday, July 21st. Atlantic Securities lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price objective on the stock. in a research report on Friday, July 21st. Finally, Alembic Global Advisors lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $143.70.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.